Glax­o­SmithK­line makes big down pay­ment on biotech tar­get­ing 'syn­thet­ic vi­a­bil­i­ty' with start­up fund­ing, pipeline deals

Since join­ing British drug­mak­er Glax­o­SmithK­line in 2018, CSO Hal Bar­ron has pushed to beef up the com­pa­ny’s on­col­o­gy port­fo­lio, tak­ing a par­tic­u­lar eye to “syn­thet­ic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER